Table 3 HRs (95% CIs) for mortality according to serum 25(OH)D concentrations among participants with OA
| Â | Serum 25(OH)D concentrations (nmol/L) | P trend | |||
|---|---|---|---|---|---|
< 25.00 | 25.00–49.99 | 50.00–74.99 | ≥ 75.00 | ||
All-cause mortality | |||||
 Number of deaths (%) | 24 (24.00) | 126 (21.39) | 173 (18.12) | 115 (12.61) |  |
 Model 1 HR (95% CI) P-value | 1.00 | 0.78 (0.50, 1.20) 0.25 | 0.65 (0.42, 0.99) <0.05 | 0.59 (0.38, 0.92) 0.02 | <0.01 |
 Model 2 HR (95% CI) P-value | 1.00 | 0.59 (0.38, 0.92) 0.02 | 0.42 (0.27, 0.66) <0.01 | 0.38 (0.24, 0.60) <0.01 | <0.01 |
 Model 3 HR (95% CI) P-value | 1.00 | 0.53 (0.29, 0.96) 0.04 | 0.43 (0.24, 0.77) <0.01 | 0.44 (0.24, 0.81) <0.01 | 0.02 |
CVD mortality | |||||
 Number of deaths (%) | 4 (4.00) | 20 (3.40) | 31 (3.25) | 19 (2.08) |  |
 Model 1 HR (95% CI) P-value | 1.00 | 0.76 (0.26, 2.23) 0.62 | 0.73 (0.26, 2.06) 0.55 | 0.57 (0.19, 1.66) 0.30 | 0.09 |
 Model 2 HR (95% CI) P-value | 1.00 | 0.62 (0.21, 1.87) 0.40 | 0.47 (0.16, 1.40) 0.18 | 0.37 (0.12, 1.15) 0.08 | 0.57 |
 Model 3 HR (95% CI) P-value | 1.00 | 0.16 (0.04, 0.60) <0.01 | 0.19 (0.05, 0.68) 0.01 | 0.18 (0.05, 0.68) 0.01 | 0.41 |
Cancer mortality | |||||
 Number of deaths (%) | 3 (3.00) | 20 (3.40) | 34 (3.56) | 21 (2.30) |  |
 Model 1 HR (95% CI) P-value | 1.00 | 0.98 (0.29, 3.31) 0.98 | 1.00 (0.31, 3.26) 1.00 | 0.86 (0.26, 2.89) 0.81 | 0.24 |
 Model 2 HR (95% CI) P-value | 1.00 | 0.85 (0.25, 2.91) 0.80 | 0.81 (0.24, 2.73) 0.73 | 0.64 (0.18, 2.26) 0.49 | 0.10 |
 Model 3 HR (95% CI) P-value | 1.00 | 0.65 (0.17, 2.41) 0.52 | 0.63 (0.17, 2.35) 0.49 | 0.47 (0.12, 1.87) 0.28 | 0.40 |